What Researchers Did
Researchers presented a case report of a 68-year-old man who developed metronidazole-induced encephalopathy potentially linked to hyperbaric oxygen therapy.
What They Found
The patient, treated for mandibular osteomyelitis with metronidazole for 49 days and five hyperbaric oxygen therapy sessions, developed peripheral neuropathy, speech disturbance, nausea, and gait disturbance after 47 days of metronidazole treatment.
Brain magnetic resonance imaging revealed hyperintense lesions in the cerebellar dentate nuclei, consistent with metronidazole-induced encephalopathy, and his ataxic symptoms improved within 15 days after discontinuing metronidazole.
What This Means for Canadian Patients
Canadian patients receiving metronidazole, especially alongside hyperbaric oxygen therapy, should be monitored for neurological side effects like speech disturbance or gait issues.
Early recognition and discontinuation of metronidazole can lead to symptom improvement.
Canadian Relevance
This study has no direct Canadian connection.
Study Limitations
This study is limited as it is a single case report, which restricts the generalizability of its findings.